Showing 5601-5610 of 8845 results for "".
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- FDA Approves SciBase's Nevisense for Melanoma Detectionhttps://practicaldermatology.com/news/fda-approved-scibases-nevisense-for-melanoma-diagnosis/2458136/The FDA has approved the Scibase Pre-Market Approval (PMA) for Nevisense, a device for the early detection of malignant melanoma. According to the letter from the FDA the device is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melano
- Braun Survey: Many Men Fret About Sensitive Skinhttps://practicaldermatology.com/news/braun-survey-many-men-fret-over-sensitive-skin/2458133/Dry, sensitive or red skin is a major key cause for anxiety among UK men, and this often impedes upon their quality of life, according to a new survey from Braun. More than one in three (34 percent) of the 7,074 men surveyed described their sk
- Congrats! ASDSA SUNucate Initiative Named Power of A Gold Award Winnerhttps://practicaldermatology.com/news/congrats-asdsa-sunucate-initiative-named-power-of-a-gold-award-winner/2458134/The American Society for Dermatologic Surgery Association (ASDSA) received a Power of A Gold Award from the American Society of Association Executives (ASAE) for its SUNu
- Common Soap Ingredient May Alter Skin's Wettabilityhttps://practicaldermatology.com/news/common-soap-ingredient-may-alter-skins-wettability/2458139/New research suggests that it is possible to alter the wettability of your skin using an ingredient commonly found in cosmetic cleaners. In a recent study, Guy German, PhD, an assistant professor of biomedical engineering at Binghamton University, State University of New York, along with
- HydroLotion Scores National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/hydrolotion-scores-national-eczema-association-seal-of-acceptance/2458138/Theraplex Company’s HydroLotion Daily Skin Moisturizer now has the National Eczema Association (NEA) Seal of Acceptance. The light-weight moisturizer for the face and body is hypoallergenic, noncomedogenic, and free of fragrances, preservatives
- ASDS: Percentage of Us Wanting Cosmetic Surgery Doubled Since 2013https://practicaldermatology.com/news/asds-percentage-of-us-wanting-cosmetic-surgery-doubled-since-2013/2458141/Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASDS Consumer
- Study Tallies Adverse Events Reported to FDA for Cosmeticshttps://practicaldermatology.com/news/study-tallies-adverse-events-reported-to-fda-for-cosmetics/2458144/There were 5,144 adverse events reported to the US Food and Drug Administration (FDA) for cosmetics and personal care products from 2004 to 2016, an average of 396 events per year, according to a new research letter published by
- Stratpharma AG's Wound Care Products Come to the UShttps://practicaldermatology.com/news/stratpharma-ags-wound-care-products-come-to-the-us/2458148/Stratpharma’s wound care and scar management portfolio is now available in the US, according to Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company. The portfolio include
- FDA Approves New Antibiotic for Skin Infectionshttps://practicaldermatology.com/news/fda-approves-new-antibiotic-for-skin-infections/2458149/The FDA has approved Melinta Therapeutics' Baxdela (delafloxacin) for adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathog